T
Tanya Coleman
Researcher at AstraZeneca
Publications - 24
Citations - 1032
Tanya Coleman is an academic researcher from AstraZeneca. The author has contributed to research in topics: Tyrosine kinase & Proto-oncogene tyrosine-protein kinase Src. The author has an hindex of 12, co-authored 24 publications receiving 964 citations. Previous affiliations of Tanya Coleman include University of Surrey & Royal Hallamshire Hospital.
Papers
More filters
Journal ArticleDOI
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine,Lorraine Mooney,Elaine Kilgour,Andrew Peter Thomas,Katherine Al-Kadhimi,Sarah Beck,Claire Rooney,Tanya Coleman,Dawn Baker,Martine J. Mellor,A. Nigel Brooks,Teresa Klinowska +11 more
TL;DR: The findings show that AZD4547 is a novel selective small-molecule inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclinical models and is under clinical investigation for the treatment ofFGFR-dependent tumors.
Journal Article
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
TL;DR: It is indicated that CYP2D6, CYP1A2 and, to a lesser extent CYP3A4, may have a role in protecting against Parkinson's disease induced by MPTP and other potential environmental neurotoxins.
Journal ArticleDOI
Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).
TL;DR: A strong correlation between drug modulation of MRP2 and PXR mRNA expression levels was evident, indicating possible post-translational regulation of digoxin secretion.
Journal ArticleDOI
Intestinal Ciprofloxacin Efflux: The Role of Breast Cancer Resistance Protein (ABCG2)
Iain S. Haslam,Jamie A. Wright,Derek A. O'Reilly,David J Sherlock,Tanya Coleman,Nicholas L. Simmons +5 more
TL;DR: BCRP is likely to be the dominant transport mechanism for ciprofloxacin efflux in both rat and human jejunum, and is a substrate for human and rodent BCRP.
Journal ArticleDOI
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
TL;DR: A novel regulatory loop is described, whereby activation of FXR by statins increases PXR reporter gene expression, potentially enhancing PxR-mediated responses, and has important potential implications for their use within a polypharmacy paradigm.